Issuer: Mainz BioMed N.V.
/ Key word(s): Annual Results
Mainz Biomed Provides Full Year 2022 Financial Results BERKELEY, US - MAINZ, Germany - April 10, 2023 - Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022. "Throughout the year we operated in a position of financial strength enabling us to achieve meaningful growth across commercial, operational and product development fronts," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "Heading into fiscal 2023, we have a defined set of priorities intended to facilitate our goal of becoming the leading developer of premier cancer-focused early detection and disease prevention molecular diagnostics." Key Highlights and 2022 Accomplishments
Consolidated Statements of Financial Position
Consolidated Statements of Comprehensive Loss
About ColoAlert About Colorectal Cancer About Mainz Biomed NV
For media inquiries, please contact press@mainzbiomed.com MC Services AG In the US: Spectrum Science For investor inquiries, please contact info@mainzbiomed.com Forward-Looking Statements
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Mainz BioMed N.V. |
Robert-Koch-Strasse 50 | |
55129 Mainz | |
Germany | |
Internet: | mainzbiomed.com |
EQS News ID: | 1603619 |
End of News | EQS News Service |